Jounce Therapeutics Named a 2013 "Fierce 15" Biotech Company by FierceBiotech

Jounce Therapeutics Named a 2013 "Fierce 15" Biotech Company by FierceBiotech

CAMBRIDGE, Mass., Sep 24, 2013 (BUSINESS WIRE) -- Jounce Therapeutics, Inc., a company focused on the discovery and development of first-in-class cancer immunotherapies, today announced that the company has been named by FierceBiotech as one of 2013's Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's eleventh annual Fierce 15 selection.

"Jounce is a classic Third Rock startup," says John Carroll, editor of FierceBiotech. "It's got a big bankroll, a hot target - incorporating several pathways involved in immunotherapy - and a slate of some of the top scientists in their field. It's also got a team of Third Rock's in-house experts to get everything going and build a team of professionals. Third Rock has one of the most exciting models for biotech creation in the industry. And Jounce is going places that has already attracted some of the industry's top R&D players."

Jounce Therapeutics was launched by Third Rock Ventures in February this year through a $47 million Series A financing and was founded by world leaders in the fields of tumor immunobiology and clinical and translational medicine in oncology. The company is developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce's proprietary product engine has the potential to discover novel biological insights to drive the development of new immunotherapy treatments with durable responses, extending and improving patients' quality of life.

"It is an honor to be recognized in the Fierce 15 class of 2013 for our transformational approach to cancer therapy," said Cary Pfeffer, M.D., interim chief executive officer of Jounce. "With the recent advances in the field, this is an exciting time for the discovery and development of breakthrough cancer immunotherapies. Jounce's world-leading team and proprietary approach positions us at the forefront of the space as we rapidly advance our pipeline and work toward achieving our goal of developing new cancer treatments that significantly improve patients' long-term survival."

The Fierce 15 celebrates the spirit of being "fierce" - championing innovation and creativity, even in the face of intense competition. A complete list of "Fierce 15" companies is available online at FierceBiotech.com.

About FierceBiotech

An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signing up is free.

About Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce's proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients' quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

SOURCE: Jounce Therapeutics

Pure Communications, Inc. Katie Wilson, 910-509-3977 [email protected]

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.